Tempest Therapeutics, Inc. (TPST) Misses Q2 EPS by 179c

Tempest Therapeutics, Inc. (NASDAQ: TPST) reported Q2 EPS of ($2.07), $1.79 worse than the analyst estimate of ($0.28).

For earnings history and earnings-related data on Tempest Therapeutics, Inc. (TPST) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• SpaceX short interest at 5-7% of float - S3 Partners
• UK’s EG Group reportedly files for US IPO worth about $1 billion